WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
CAMBRIDGE, Mass., Feb. 11, 2016 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, February 18, 2016, at 8:30 a.m. ET to report its fourth quarter and full year 2015 financial results and discuss recent clinical development and corporate activities.
The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 40733168. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contact: Renee Leck, Senior Manager, Investor and Public Relations [email protected] 617-649-8299
